International Journal of Pharmaceutical Research and Applications
Volume 9, Issue 6 Nov - Dec 2024, pp: 856-867 www.ijprajournal.com ISSN: 2456-4494

# Therapeutic application of monoclonal antibodies: A review

Sana Nusrat Praween[1],Tanya Sharma[2] Dr. Kaushal Kishore Chandrul[3]
*1Student Of M.Pharma { Final year}, 2 HOD Of Pharmacy,3Dean of Pharmacy*
*Department Of Pharmacy , Mewar University Chittorgarh (Rajasthan),India*

Date of Submission: 01-12-2024 Date of Acceptance: 10-12-2024

**ABSTRACT**
Overview. An essential family of proteins called antibodies is created when the body mounts an immunological defense against a foreign substance. Antibodies fall into five main classes: IgM, IgG, IgA, IgD, and IgE. Immunoglobulins vary in their structure and immunological activity. Multiple disulphide linkages bind the two light and two heavy chains that make up an antibody. On light and heavy chains, there are variable portions called the fragment antigen-binding (Fab) area and a constant region called the fragment crystallizable (Fc) region. As a class, antibodies are broad-spectrum antimicrobial drugs that can combat any type of disease.
Individual antibodies, however, are typically pathogen-specific. Antibody engineering methods including hybridoma, phage display, and transgenic technologies can be used to create monoclonal antibodies, which only identify one epitope of the cognate antigen. Antibody fragments like Fab, scFv, and diabodies are produced when the complete constant region or a piece of the entire Fc area is removed. Antibody fragments are more suitable for therapy than the entire antibody because of their superior tissue or tumor penetration properties. Aim. By altering their structural or functional characteristics, antibodies can now be used for a variety of therapeutic purposes.
**Keywords:** Monoclonal antibodies, Therapeutic application, Infectious diseases, Cancer, Auto-immune diseases, Metabolic disorders, radio immunotherapy.

## I. INTRODUCTION:-

Vertebrates' immune systems are always changing to defend against various invasive infections. Adaptive processes like the production of antibody (Ab) molecules, which can bind to all molecular structures of the microbial pathogen (bacteria, viruses, fungi, nematodes, and other parasites) and keep up with the various mutations in an organism, are among the innate mechanisms that the immune responses revolve around. A molecule or portion of a molecule that the immune system may identify as a foreign substance is known as an antigen.

Thus, the immune system's issue is addressed in two ways.

First, by rearranging and rearranging the genetic components of a pathogen's new antigen (epitope), B cells generate a variety of antibodies specific for that antigen.

Second, the antibody's paratope-encoding genes undergo quick mutations in order to adapt to and firmly engage with the antigen's epitope. As a result, these produced antibodies have higher affinity and higher specificity for binding to the antigen.

Because they can identify and bind strongly and specifically with the appropriate antigens, antibodies are therefore valuable research tools in diagnosis and treatment.
Different anti-bodies produced in the blood of immunized animals from various cell types are present in polyclonal antibody mixtures. Since the majority of antigens have several epitopes, they can promote the growth and differentiation of distinct B-cell clones. As a result, a diverse pool of serum antibodies that are specific for a certain antigen epitope or epitopes can be generated.

Monoclonal antibodies (MAb(s)), on the other hand, are a mixture of homogeneous antibody molecules that have affinity for a particular antigen. They are frequently produced by fusing a B-cell with a single lineage of cells that have a specific antibody gene using a hybridoma.
Ultimately, the same antibody is secreted by a population of identical cells, often known as clones.

MAbs are superior to polyclonal antibodies because of their great repeatability and specificity when generated utilizing culture procedures. MAbs are in high demand in the business because to their growing use in research and diagnosis, pharmaceuticals for cancer and immunological disorders, and pharmacy.

International Journal of Pharmaceutical Research and Applications
Volume 9, Issue 6 Nov - Dec 2024, pp: 856-867 www.ijprajournal.com ISSN: 2456-4494

The key features that give MAbs their therapeutic usefulness are their homogeneity and specificity of binding, as well as their capacity for infinite production.2. Another distinct

The ability to produce particular antibodies using a combination of antigens is an advantage of hybridoma creation. This also makes it possible to isolate a single cell clone by screening a desired antibody from a population of antibodies using a purified antigen.1–2 For these reasons, this review's goal was to analyze the many aspects of MAbs' suitability for illness monitoring and diagnosis.

**History:-**

Georges Kohler of West Germany and Cesar Milstein of Argentina developed the generation of MAbs by hybridoma technology in 1975. They shared the Nobel Prize for Physiology and Medicine in 1984 with Niels Kaj Jerne of Denmark. In 1976, Kohler and Milstein created a method for fusing tumorous myeloma cells with splenocyte cells that had been isolated from an immunized mouse's spleen. The hybrid cells were clones of cells that produced antibodies against a specific antigen and multiplied quickly to generate vast quantities of antibodies.

The hybridoma can sustain the antibody genes of mouse spleen cells due to its high antibody secretion rates and rapid proliferation, as seen in myeloma cells. Greg Winter employed the first humanized MAbs in 1988 in order to prevent the reactions and responses seen in patients who received injections of murine-derived MAbs.

**Antibodies:-**

Glycoprotein molecules called antibodies are found in serum. They are created in reaction to antigens, which can be either foreign or foreign proteins or polysaccharide molecules. B-lymphocytes are a type of blood cell that secretes antibodies. Every antibody generated is unique to the specific antigen that triggered its synthesis.Antibodies can be divided into five categories.

Major classes, including IgM (Pentamer), IgD (monomer), IgE (monomer), IgG (monomer), and IgA (Dimer).

Immunoglobulin (Ig) is another name for antibodies. They have two chains, such as a heavy chain, light chain, constant region, variable region, and di sulfide bond, among others.



Structure of an antibody

**Function of antibodies:-**

Antibodies have defensive properties and can identify particular antigens on target diseases. Neutralization of viruses and toxins is one of the protective effects; antibody binding alone produces enough steric interference to break the connection between the antigen and the cellular receptor, preventing virus uptake and reproduction or poisoning. However, the attached antibody's ability to attract additional immune system components results in additional protective effects such complement activation, antibody dependent cellular

International Journal of Pharmaceutical Research and Applications
Volume 9, Issue 6 Nov - Dec 2024, pp: 856-867 www.ijprajournal.com ISSN: 2456-4494

cytotoxicity (ADCC), and phagocytosis activity. This happens as a result of complement protein binding in the serum or Fc receptors on immune cell surfaces that bind to the Fc portion of the antibody. Recently, it was discovered that antibodies had direct antifungal and in vitro antibacterial effects in addition to cell-mediated immune and inflammatory response regulatory properties.




**Fig.:- Overview of the natural function of antibodies**

**Classification of antibodies:**

Antibodies fall into five main classes: IgM, IgG, IgA, IgD, and IgE. The structure and immunological function of these immunoglobulins vary. IgG antibodies are the predominant kind of immunoglobulin present in serum and have a monomer structure. Due to its dominance in the initial immune responses to the majority of antigens, IgM, which has a pentameric shape, is clinically significant. The main immunoglobulin found in saliva, tears, nasal mucosa, prostatic fluid, and numerous other body fluids is IgAs, which are polymeric. Monomeric IgD antibodies are detected on the surface of human B cells and in trace concentrations in serum.

IgE antibodies make up a very minor portion of all blood antibodies and are found in serum in a monomeric state. They contribute to the synthesis and release of molecules that trigger inflammation, including histamine and other vasoactive mediators. About 75% of the total serum immunoglobulins in healthy persons are made up of the four-polypeptide chain IgG monomer.

International Journal of Pharmaceutical Research and Applications
Volume 9, Issue 6 Nov - Dec 2024, pp: 856-867 www.ijprajournal.com ISSN: 2456-4494

| The Five Immunoglobulin (Ig) Classes | | | | | |
|---|---|---|---|---|---|
| Properties | IgG monomer | IgM pentamer | Secretory IgA dimer | IgD monomer | IgE monomer |
| Structure |  |  |   |  |  |
| Heavy chains | γ | μ | α | δ | ε |
| Number of antigen-binding sites | 2 | 10 | 4 | 2 | 2 |
| Molecular weight (Daltons) | 150,000 | 900,000 | 385,000 | 180,000 | 200,000 |
| Percentage of total antibody in serum | 80% | 6% | 13% (monomer) | <1% | <1% |
| Crosses placenta | yes | no | no | no | no |
| Fixes complement | yes | yes | no | no | no |
| Fc binds to | phagocytes | | | | mast cells and basophils |
| Function | Neutralization, agglutination, complement activation, opsonization, and antibody-dependent cell-mediated cytotoxicity. | Neutralization, agglutination, and complement activation. The monomer form serves as the B-cell receptor. | Neutralization and trapping of pathogens in mucus. | B-cell receptor. | Activation of basophils and mast cells against parasites and allergens. |

**FIG :-The structure of five immunoglobulin (ig) classes.**

**Procedure for the Production of monoclonal antibody:**

The fundamental procedures used to produce a monoclonal antibody are:

1. Immunization (Immunize the animal)
2. Cell fusion process
3. Selection of hybridomas
4. Screening the products
5. Cloning and propagation
6. Characterization and storage




**Diag. Production of monoclonal antibody**

International Journal of Pharmaceutical Research and Applications
Volume 9, Issue 6 Nov - Dec 2024, pp: 856-867 www.ijprajournal.com ISSN: 2456-4494

**1. Immunization:-**

In hybridoma technology, immunizing a mouse or other animal with the proper antigen is the initial step. The antigen is injected subcutaneously together with an adjuvant, such as Freund's complete or incomplete adjuvant. Several times, the injections are made at various locations.

This makes it possible for B-lymphocytes that are reacting to the antigen to be stimulated more. An intravenous last dosage of the antigen is given three days before the animal is killed. This strategy has maximized the growth of immune-stimulated cells for antibody production. Throughout the immunization process, the animal's serum is frequently tested for the concentration of the target antibodies.

The animal is killed when the antibody concentration in the serum reaches the ideal level. To liberate the cells, the spleen is aseptically removed and broken up using mechanical or enzymatic techniques. Density gradient centrifugation is used to separate the splenic lymphocytes from the other cells.

When the serum antibody concentration reaches the optimal level, the animal is euthanized. The spleen is aseptically removed and broken up using mechanical or enzymatic methods in order to release the cells. The splenic lymphocytes and other cells are separated using density gradient centrifugation.

**2. Cell Fusion process:**

HGPRT negative myeloma cells are combined with the spleen cells, which are lymphocytes that have been completely cleaned. Since polyethylene glycol (PEG) is hazardous, the cell mixture is only exposed to it for a few minutes. The cells are maintained in a new medium once the PEG is eliminated by washing. These cells are made up of free myeloma cells, free lymphocytes, and hybridomas, or merged cells.

Condition for Fusion Procedure: The mouse system must meet the following requirements before the fusion is performed:

• Logarithmic growth phase myeloma cells;
• 2–5 lymphocytes per myeloma cell
• 40% PEG (1000dal); PEG should be avoided due to its cytotoxic effects.
• Fusion for three minutes at 37°C and pH 7.5–8.0

**3. Selection of Hybridomas:**

When the cells are cultured in HAT medium only the hybridoma cells grow, while the rest will slowly disappear. This happens in 7-10 days of culture. Selection of a single antibody producing hybrid cells is very important. This is possible if the hybridomas are isolated and grown individually. The suspension of hybridoma cells is so diluted that the individual aliquots contain on a average one cell each. These cells, when grown in a regular culture medium, produce the desired antibody.

**4. Screening the Products:**

It is necessary to check if the hybridomas secrete the desired specificity of antibodies. Every hybridoma culture's culture media is routinely examined for the required antibody specificity. For this, the two methods—ELISA and RIA—are frequently employed. The antibody binds to the particular antigen (often coated on plastic plates) in both experiments, and the unbound antibody and other medium ingredients can be removed by washing. Consequently, screening can be used to determine whether hybridoma cells are generating the desired antibodies. Monoclonal antibody is the name given to the antibody that the hybrid cells release.

**5. Cloning and Propagation:**

They separate and clone the single hybrid cells that are generating the required antibody. For cloning hybrid cells, two methods are frequently used:

- The soft agar approach and
- The limited dilution method.

The limiting dilution approach involves serially diluting the hybridoma cell solution and then placing aliquots of each dilution into microculture wells. The dilutions are prepared so that there is just one hybrid cell in each aliquot in a well. This guarantees the production of a monoclonal antibody.

The hybridoma cells are cultivated in soft agar using the soft agar method. Numerous cells can be grown in semisolid media at the same time to create colonies. The nature of these colonies will be monoclonal. In practice, each of the aforementioned methods are combined to produce MAbs as much as possible.

**6. Characterization and Storage:-**

To achieve the required specificity, the monoclonal antibody must undergo biochemical and biophysical characterisation. Clarifying the MAb's specificity for a particular epitope, its

International Journal of Pharmaceutical Research and Applications
Volume 9, Issue 6 Nov - Dec 2024, pp: 856-867 www.ijprajournal.com ISSN: 2456-4494

number of binding sites, and its immunoglobulin class or subclass is also crucial.

Both the MAbs and the cell lines' stability are crucial. It is necessary to describe the cells' (and MAbs') resistance to freezing and thawing. At various phases of cloning and culture, the target cell lines are frozen in liquid nitrogen.

**NANOTECHNOLOGY'S POTENTIAL IMPACT ON MABS:**

Diagnostic and therapeutic applications are the two main biomedical uses for antibody-conjugated nanoparticles.

The two primary uses of antibody-conjugated nanoparticles in therapy are tissue healing and the creation of tailored medication delivery. Applications in diagnosis include contrast agents for magnetic resonance imaging (MRI), sensing, cell sorting, bioseparation, enzyme immobilization, immunoassays, transfection (gene delivery), purification, and in vitro experiments. These applications can be separated into in vivo and in vitro experiments.

Bulk form, when materials exhibit consistent physical characteristics across all sizes. Antibodies are biological substances with a nanoscale size that belong to a particular immune system. They may carry various elements (toxins, drugs, fluorochroms, or even nanoparticles, etc.) and be used in various diagnostic procedures or even in therapy to destroy a specific target. This is in addition to their own properties as pathogens or toxin neutralizers and in the recruitment of immune elements (complement, improving phagocytosis, cytotoxicity antibody dependent by natural killer cells, etc.). Antibodies and nanoparticles can conjugate to produce a product that combines their respective qualities.

Researchers are interested in using nanomaterials for pharmaceutical applications, particularly in the field of drug delivery, because the characteristics of materials vary greatly between the atomic or subatomic level and larger scales. Some of the disadvantages of large-size materials are addressed by this approach, including poor intestinal absorption, in vivo stability, solubility, sustained and focused distribution to the site of action, and widespread adverse effects. According to reports, nanostructures can shield medications from deterioration in the gastrointestinal system, and even additionally, to offer ways to avoid the liver and stop the first pass metabolism. Additionally, this technology allows for the targeted distribution of medications to different parts of the body and enable delivery of medications with limited water solubility.

Additionally, nanotechnology controls the release of medications by increasing their bioavailability and enabling them to stay in the bloodstream for an extended period of time. Drugs can be efficiently delivered to their intended locations of action thanks to nanostructures' ability to enter tissues and be readily absorbed by cells. According to reports, cells can absorb nanostructures 15–250 times faster than they can microparticles. Drugs that perform poorly in clinical trial phases may potentially function better thanks to nanotechnology, which also increases the acceptability and performance of dosage forms. Without a doubt, nanotechnology will transform the field of drug delivery and assist in resolving the main issues with traditional medications used to treat and manage chronic illnesses like diabetes, cancer, asthma, hypertension, and HIV.

**APPLICATION OF ENGINEERED ANTIBODIES FOR THERAPEUTIC PURPOSES:-**

Antibody engineering as an opportunity for selection and optimization of anti-HIV therapeutic agents

The cause of acquired immunodeficiency syndrome (AIDS) is the Human Immunodeficiency Virus type 1 (HIV-1). The quality of life for many infected people has significantly improved since the advent of highly active antiretroviral therapy (HAART), and the death rate from AIDS has significantly decreased. However, there are three main shortcomings with the antiretroviral medications now on the market: 1) The medications have comparatively high toxicities, which might result in myocardial infarction and other unwanted side effects;

2) Since reverse transcriptase inhibitors are active after infection, their pharmacological activity is cell-dependent; and 3) HIV has a high rate of mutation, which causes treatment-resistant viral variations to emerge quickly. These factors contribute to the fact that many HAART-treated patients continue to experience suboptimal control over HIV-1 infection and progression.

drug resistance is a result of antiretroviral medications' failure. As a result, alternative approaches to intervention that limit viral replication are required. In HIV treatment, medications that target the cellular receptor complex show promise, and they are also a good target for viruses that are resistant to many drugs.

International Journal of Pharmaceutical Research and Applications
Volume 9, Issue 6 Nov - Dec 2024, pp: 856-867 www.ijprajournal.com ISSN: 2456-4494

**Anti-HIV antibodies currently in clinical trial:-**

Table 1 summarizes the key features of the antibodies that have already been tested in clinical settings as HIV entrance inhibitors. Humanized IgG4 mAb Ibalizumab, a monoclonal antibody that binds to the second (C2) domain of CD4, was originally known as TNX-355 and Hu5A8. Ibalizumab, in contrast to attachment inhibitors, reduces CD4's flexibility, which prevents the CD4 gp120 complex from attaching to CD4 but still blocks its access to the co-receptors CCR5 and CXCR4. In vitro, this monoclonal antibody is a strong inhibitor of HIV-1 and exhibits synergy with other anti-HIV medications or the fusion inhibitor enfuvirtide .

| Antibody Name | Target Ag | Origin | Isotype | Trial status |
|---|---|---|---|---|
| **HGS004** | CCR5 | Human mAb | IgG4 | I |
| **PRO140** | CCR5 | Humanized mAb | IgG4 | I |
| **Ibalizumab** | CD4 | Humanized mAb | IgG4 | II |
| **PRO542** | Gp120 | Human fusion protein | IgG2 | II |

Table: 1

**Antibody therapeutics for cancer therapy:**

Over the past few decades, the usage of monoclonal antibodies (mAbs), a class of medicinal biologics, has grown. Paul Ehrlich first put up the idea of use antibodies to specifically target cancers more than a century ago.

**Mechanism of action of monoclonal antibodies for the treatment of cancer Altering signal transduction in the downstream intracellular pathways.**

Cancer cells have a variety of cell surface receptors that trigger internal processes that promote proliferation. These include EGFR or ErbB1, ErbB2 or HER-2/Neu, HER-3, and HER-4, which belong to the same family and are overexpressed in epithelial cancers that start in the head and neck, breast, lung, and colon. This causes the disease to spread quickly and increases the risk of metastasis. Anti-EGFR antibodies attach to the receptor domain of the EGFR receptor, preventing downstream activation of the receptor and enhancing receptor internalization. Antibodies impede the cancer cell cycle, which results in apoptosis.

Cancer cells have a variety of cell surface receptors that trigger internal processes that promote proliferation. These include EGFR or ErbB1, ErbB2 or HER-2/Neu, HER-3, and HER-4, which belong to the same family and are overexpressed in epithelial cancers that start in the head and neck, breast, lung, and colon. This causes the disease to spread quickly and increases the risk of metastasis. Anti-EGFR antibodies attach to the receptor domain of the EGFR receptor, preventing downstream activation of the receptor and enhancing receptor internalization. Antibodies impede the cancer cell cycle, which results in apoptosis.

Mechanism of action of monoclonal antibodies for the treatment of cancer:-modifying the downstream intracellular pathways' signal transduction. Cancer cells have a variety of cell surface receptors that trigger internal processes that promote proliferation. These include EGFR or ErbB1, ErbB2 or HER-2/Neu, HER-3, and HER-4, which belong to the same family and are overexpressed in epithelial cancers that start in the head and neck, breast, lung, and colon. This causes the disease to spread quickly and increases the risk of metastasis. Anti-EGFR antibodies attach to the receptor domain of the EGFR receptor, preventing downstream activation of the receptor and enhancing receptor internalization. Antibodies impede the cancer cell cycle and induce apoptosis.

**Antibody-dependent cell cytotoxicity (ADCC):-**

The immune system destroyed the cancer cells that were coated in antibodies. In antibody-dependent cytotoxicity, neutrophils, NK cells, and macrophages are the effector cells. The Fc component of the antibody, which binds to an Fc gamma receptor (FcgR) on the effector cells, is essential for ADCC. ADCC happens when the mAb's Fab and Fc regions bind to an activating FcgR and a tumor cell antigen, respectively, forming a bridge connecting the tumor cell and the effector cell.

Following target cell recognition, effector cells launch a lytic attack on the target cell.

International Journal of Pharmaceutical Research and Applications
Volume 9, Issue 6 Nov - Dec 2024, pp: 856-867 www.ijprajournal.com ISSN: 2456-4494

**Complement-mediated cytotoxicity (CDC):-**
A sequence of complement proteins mediates a cytolytic cascade that causes CDC, which lyses the antibody-bound cell.

**Soluble ligand neutralization:-**

Antibodies have the potential to attach to circulating proteins and prevent them from locating their targets, which aids in the tumors' growth. The fully-humanized monoclonal antibody bevacizumab, which targets VEGF-A, is a significant illustration of this approach. Bevacizumab inhibits angiogenesis and, consequently, tumor growth and proliferation by binding to and deactivating the biological activity of VEGF-A.

**Cytotoxic drug delivery:-**

Because they have fewer systemic side effects, tumor-targeted monoclonal antibodies are attached to cytotoxic medicines to deliver them precisely to the tumor cells [54]. The HER2-directed antibody-drug conjugate trastuzumab-DM1 T-DM1 and the CD30-directed antibody-drug conjugate brentuximab vedotin are two intriguing examples of this technique [51]. Aside from human cancer therapy, very few antibody therapeutics are being researched for animal cancer. For example, the Kansas City, USA-based pet health business Aratana Therapeutics is creating antibody treatments for dogs. In 2012, the canine lymphoma monoclonal antibody AT-005 (against CD52) was authorized for the treatment of canine T-cell lymphoma.

**The use of antibodies in the treatment of infectious diseases:**

Anti-bacterial antibodies:- Bacterial exotoxins are the target of antibiotic therapy. For example, B. anthracis generates a powerful bioweapon called a tripartite exotoxin, which is made up of edema factor (EF), lethal factor (LF), and protective antigen (PA). Rabbits and monkeys were protected against a deadly inhalational anthrax challenge by post-exposure prophylaxis with mAb against PA, while rats were protected against a challenge with a lethal toxin, a combination of PA and LF, by mAb against LF [57]. For protection against inhaled anthrax, an anti-PA mAb works in concert with the antibiotic ciprofloxacin .

Severe gastrointestinal disorders are brought on by Escherichia coli, a major exotoxin-producing bacterium that produces Shiga toxin. When toxins enter the bloodstream, they can cause fatalities, hemolytic uraemic syndrome, and acute renal failure.

There are only supportive treatments available at the moment. a human IgG1 mAb produced against the Shiga toxin component in transgenic mice When given to piglets after the onset of diarrhea, A avoided deadly systemic consequences. Other exotoxins that mAbs have been demonstrated to be somewhat effective against include the eubacteria Clostridium perfringens epsilon toxin, Pseudomonas aeruginosa exotoxin A, and Clostridium botulinus neurotoxin. Even so, exotoxin targeting necessitates an initial characterisation of the exotoxin and prior knowledge of the infectious agent's pathophysiology.

As a result, areas of the genetic makeup of surface carbohydrates that exhibit comparatively minimal variation among bacterial subtypes are investigated as possible target antigens. Since various bacterial species frequently display heterogeneity in their carbohydrate side-chain residues, antibodies target shared or invariant epitopes, such as the core carbohydrate backbone. Additionally, it works to avoid septic shock by encouraging the bloodstream to rid itself of LPS endotoxin. While MAbs produced against the inner core LPS of different Neisseria meningitides serotypes have demonstrated low phagocytic activity despite their avidity for whole-cell bacteria and poor binding to full-length LPS, carbohydrates targeting mAbs have produced conflicting outcomes.

Mice were protected from a bacterial challenge by MAbs generated against the deacetylated core carbohydrate backbone of the S. aureus surface carbohydrate, poly-N-acetylglucosamine (PNAG), which also outperformed mAbs against a completely acetylated wild type PNAG .

**Antibodies and viral disease:-**

As a preventative measure against the viral illness Respiratory Syncytial Virus (RSV), palivizumab—the only monoclonal antibody now available for use in the treatment of infectious diseases—was created. The effectiveness of mAb therapy in viral disorders is still up for debate, despite the fact that mAbs have been demonstrated to be capable of neutralizing a wide variety of viral infections in vitro. This is because it is unclear how much viral clearance relies on antibody-mediated immunity. Usually, T cell-mediated adaptive

International Journal of Pharmaceutical Research and Applications
Volume 9, Issue 6 Nov - Dec 2024, pp: 856-867 www.ijprajournal.com ISSN: 2456-4494

immunity is involved in the removal of a viral infection. By destroying virus-infected cells, CD8+ T cells stop the virus from replicating and lower its load.

Neutralizing therapeutic antibodies, on the other hand, ought to be prepared to assist in acute infections by preventing viral reproduction and viremia, allowing the host system to build an effective defense against viral removal. In addition to their ability to neutralize viruses, antibodies can also activate natural killer (NK) cells that mediate ADCC, which in turn can aid in the destruction of infected cells that express viral proteins on their surface .

**In the treatment of autoimmune diseases:**

Autoimmune conditions such as multiple sclerosis and rheumatoid arthritis are quite concerning. MAbs that target T and B cells have shown some promise in the clinical trials of patients with rheumatoid arthritis.

**MAbs in radio immunotherapy (RAIT):-**

The radioisotopes can be coupled to MAbs that target tumor cells, allowing for the concentration of radioactivity at the desired sites and a very effective killing of the target cells (tumor cells). The benefit of radio immunotherapy is that, unlike immunotoxin therapy, conjugated complexes do not need to penetrate the cells; however, the drawback is that nearby normal cells may also be damaged or killed; this can be reduced by using radioisotopes with short half-lives. Yttrium-90, which has a half-life of 64 hours, is a suitable isotope to be employed in RAIT. The shortage of yttrium-90 has led to the more common use of indium-111.

**Protein Purification**: Any protein can create monoclonal antibodies. Additionally, the protein against which the MAb was grown can be easily purified using the so-produced MAb. By connecting MAbs to cyanogen bromide activated sepharose (a chromatographic matrix), MAbs columns can be made. Protein purification using the immunoaffinity technique benefits greatly from the immobilized MAbs in this way.

MAbs have several benefits when it comes to protein purification. These consist of the MAb's high degree of purification, very effective elution from the chromatographic column, and specificity in binding to the target protein. A common method for purifying recombinant interferons is immunoaffinity chromatography. As demonstrated by the fact that interferon-α2 can be purified more than 5,000 times in a single step, this approach is clearly effective.

**FUTURE TRENDS OF MONOCLONAL ANTIBODIES:**

Bispecific antibodies, ADCs, and companion diagnostics are some noteworthy trends that seem to be emerging and should aid in determining which patient populations are best suited for therapy.

Recent advancements to increase the potency and effectiveness of Mabs show greater promise because they may allow for the prescription of lower doses and maybe reduced prices. Several strategies have been used to increase Mabs' effectiveness. The removal of glycosylation sites from the antibody's variable domain through genetic engineering is among the most promising. This improves Mabs' effector function, such as antibody-dependent cell-mediated cytotoxicity (ADCC), which triggers the patient's innate immune system to eliminate a target cell, such as cancer.

The effectiveness of Mab therapies in other domains is still unknown, despite the fact that the new generation of Mabs may significantly enhance the treatment of autoimmune diseases and cancer, two well-established disease targets. This issue is more pressing than ever in the context of infectious diseases.

Mab therapies' pathogen-specificity may make it more difficult to treat mixed infections. Targeting the wide variety of antigens that viruses carry with a cocktail of Mabs could be one way to solve the problem. This approach would successfully replicate the body's natural immune response, which occurs when a virus infects a person and causes the body to produce several antibodies in response to the antigens it presents. Each antibody binds to a distinct antigen. The immune system uses this variety of antibodies to combat the invader. Research is already underway to cure rabies by using a combination of Mabs.

New prospects for serum therapy have been made possible by recent developments in Mab engineering. The ability to create standardized agents with Mabs is crucial because it can result in a cocktail that is more accurate and effective than conventional serum therapy. There hasn't been any commercial investment in the creation of antiinfective Mab products thus far. This is partly because infectious diseases have a small market

International Journal of Pharmaceutical Research and Applications
Volume 9, Issue 6 Nov - Dec 2024, pp: 856-867 www.ijprajournal.com ISSN: 2456-4494

because they are transient. In contrast, chronic disorders like cancer and autoimmune diseases have a higher potential for profit because they require ongoing care. However, the pharmaceutical landscape is shifting due to worries about the resurgence of old pathogens (like tuberculosis), the emergence of new ones (like West Nile and corona viruses), the rise of superbugs like MRSA, the resurgence of old pathogens (like tuberculosis), the rise of immunocompromised patients due to HIV infection, organ transplantation, chronic degenerative diseases, and advancements in cancer treatment.

Similarly, Mabs have been employed in cancer research and treatment, offering effective instruments for locating and focusing on various antigens present in tumors. In recent years, Mabs therapeutics have provided alternatives to medications with a wide scope and significant toxicity, despite the fact that these applications did not immediately result in successful Mabs therapeutics for cancer. Cancer patients no longer have to worry about hair loss and other severe side effects linked to other cytotoxic medications, which has revolutionized the way they are treated.

Mabs have the advantage of being administered as maintenance therapies, which is changing our understanding of some cancers from being unavoidably fatal to being a chronic condition. Additionally, Mabs have made it possible to prescribe specific therapeutics for specific tumor antigens in individual patients, allowing for a higher level of personalization in cancer management than was previously possible. In fact, Mabs are predicted to play a bigger role in personalized cancer therapies in the future.

The opportunity for new, focused treatments and medications that can provide individualized care—as well as a window into the many, overlapping circumstances that underpin human disease—is presented by Mabs in a world of antibiotic-resistant superbugs and an aging population struggling with autoimmune diseases and cancer.

## II. CONCULSION:-

This article offers some key aspects on the justification for producing monoclonal antibodies as well as the procedures required to do so. Furthermore, some applications have been referenced for additional reading. It is undoubtedly possible to demystify monoclonal antibodies by using the mouse model and related processes for producing them. It is important to highlight, though, that alternative approaches exist and that recombinant phage antibody-derived antibodies will become more widely used in the future. Additionally, the creation of hybridomas must always be viewed as a teaching moment**.**

Several antigen peptides that were created for an amino acid sequence related to Epstein-Barr virus recently produced hybridomas that primarily produced monoclonal antibodies of the IgM isotype (PN Nelson et al, personal observation, 1999). Presumably, the peptides in this instance were unable to cause B cells to transition classes. This conclusion will therefore need to be taken into account in any future immunization approach for the development of IgG antibodies. Lastly, creating hybridomas is a difficult undertaking that should not be taken lightly.

Cells known as hybridomas have been modified to generate a specific antibody in high quantities. A proprietary technique, hybridoma technology can produce key industrial needs for a quicker, cheaper, and higher-quality process. Monoclonal antibodies are utilized in pregnancy test kits and in the detection of diseases like AIDS because they provide the needed immunity. Monoclonal antibodies are particular antibodies that have significant economic and medical value and are now a vital tool in biomedical research. It is helpful, for instance, in detecting (ABO) blood groups.

## REFERENCE:-

[1]. Bretton, PR, Melamed, MR, Fair, WR, Cote, RJ (1994). Detection of occult micrometastases in the bone marrow of patients with prostate carcinoma. Prostate. 25(2), 108-14.

[2]. Abdullah MA, Rahmah A, Sinskey AJ, Rha CK (2008) Cell Engineering and Molecular Pharming for Biopharmaceuticals. Open Med Chem J 2: 49-61.

[3]. Cowden J, Parker SK. Monoclonal antibodies: production, uses and side effects; Pediatr Infect Dis J. 2006 Jun;25(6):553-5

[4]. Third Line of Defense - Specific Immunity | Ombiology4u - Online Biology Notes | Exams | Somaliland Secondary School Lessons | Textbooks

[5]. Connolly SE, Thanassi DGandBenach JL. Generation of a complement-independent bactericidal igm against a relapsing fever borrelia. The Journal of Immunology.

International Journal of Pharmaceutical Research and Applications
Volume 9, Issue 6 Nov - Dec 2024, pp: 856-867 www.ijprajournal.com ISSN: 2456-4494

2004; 172 : 1191-1197. Link Retrieved from journal.https://doi.org/10.4049/jimmunol.172.2.1191

[6]. Casadevall AandPirofski L-a. New concepts in antibody-mediated immunity. Infection and immunity. 2004; 72 (11): 6191-6196.

[7]. Link Retrieved from journal.https://doi.10.1128/IAI.72.11.6191-6196.2004 14. Mahabeer RandBhoola KD. Kallikrein and kinin receptor genes. Pharmacology & Therapeutics. 2000; 88 (1): 77-89. Link Retrieved from journal.https://doi.org/10.1016/S0163-7258(00)00080-2

[8]. Domanski PJ, Patel PR, Bayer AS, Zhang L, Hall AE, et al. Characterization of a humanized monoclonal antibody recognizing clumping factor a expressed by staphylococcus aureus. Infection and immunity. 2005; 73 (8): 5229-5232. Link Retrieved from journal.https://doi.10.1128/IAI.73.8.5229-5232.2005 64.

[9]. Hezareh M, Hessell AJ, Jensen RC, van de Winkel JGandParren PW. Effector function activities of a panel of mutants of a broadly neutralizing antibody against human immunodeficiency virus type 1. Journal of virology. 2001; 75 (24): 12161-12168. Link Retrieved from journal.https:doi.10.1128/JVI.75.24.12161-12168.2001

[10]. Roopenian DCandAkilesh S. Fcrn: The neonatal fc receptor comes of age. Nature Reviews Immunology. 2007; 7 (9): 715-725. Link Retrieved from journal.https://doi.org/10.1038/nri2155 69.

[11]. Shinkawa T, Nakamura K, Yamane N, Shoji H, Kanda Y, et al. The absence of fucose but not the presence of galactose or bisecting n acetylglucosamine of human igg1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J. Biol. Chem. 2003; 278 (5): 3466-3473. Link Retrieved from journal.https://doi.10.1074/jbc.M210665200

[12]. Nelson AL, Dhimolea E, Reichert JM. Development trends forhuman monoclonal antibody therapeutics; Nat Rev Drug Discov.2010 Oct;9(10):767-74.

[13]. Martin Wiles and Patrik Andreassen. Monoclonals - the billiondollar molecules of the future; Fall 2006

[14]. Castillo J, Winer E, Quesenberry P. Newer monoclonal antibodiesfor hematological malignancies;: Exp Hematol. 2008 Jul;36(7):755-68.

[15]. Agulnik M. New approaches to EGFR inhibition for locallyadvanced or metastatic squamous cell carcinoma of the head andneck (SCCHN);:Med Oncol. 2012 Jan 18

[16]. Mullard A 2011 FDA drug approvals, Nature Rev Drug Disco , 2011, vol. 11(pg. 91-4) Google Scholar Crossref

[17]. Modjtahedi H. Monoclonal antibodies as therapeutic agents:advances and challenges, Iran J Immunol , 2005, vol. 2 (pg. 3-20)

[18]. Reichert JM, Valge-ArcherVE. Development trends formonoclonal antibody cancer therapeutics?, Nat Rev DrugDiscov , 2007, vol. 6 (pg. 349-56) Google Scholar CrossrefSearch ADS PubMed

[19]. Dimitrov DS, MarksJD. Therapeutic antibodies: current state andfuture trends—is a paradigm change coming soon, Methods MolBiol , 2009, vol. 525 (pg. 1-27)Google Scholar PubMed

[20]. Reichert JM. Antibody-based therapeutics to watch in 2011, mAbs , 2011, vol. 3 (pg. 76-99)Google Scholar CrossrefSearch ADS PubMed

[21]. AdlerMJ, Dimitrov DS. Therapeutic antibodies againstcancer, Hematol Oncol Clin North Am , 2012, vol. 26 (pg. 447-81) Google Scholar Crossref Search ADS PubMed

[22]. Chan AC, CarterPJ. Therapeutic antibodies for autoimmunity andinflammation , Nat Rev Immunol , 2010, vol. 10 (pg. 301-16)Google Scholar Crossref Search ADS PubMed

[23]. Shreya Talreja et al /J. Pharm. Sci. & Res. Vol. 12(1), 2020, 49-53

[24]. Abrishami, M., Ganavati, S.Z., Soroush, D., Rouhbakhsh, M., Jaafari, R., Malaekeh Nikouei, P.B., 2009. Preparation, characterization, and in vivo evaluation of nanoliposomes-encapsulated bevacizumab (Avastin) for intravitreal administration. Retina 29 (5), 699–703.

International Journal of Pharmaceutical Research and Applications
Volume 9, Issue 6 Nov - Dec 2024, pp: 856-867 www.ijprajournal.com ISSN: 2456-4494

[25]. Al Faraj, A., Shaik, A.S., Afzal, S., Al Sayed, B., Halwani, R., 2014. MR imaging and targeting of a specific alveolar macrophage subpopulation in LPS-induced COPD animal model using antibody-conjugated magnetic nanoparticles. Int. J. Nanomed. 24 (9), 1491–1503.

[26]. Al-Jamal, W.T., Kostarelos, K., 2011. Liposomes: from a clinically established drug delivery system to a nanoparticle platform for theranostic nanomedicine. Acc. Chem. Res. 44, 1094–1104.

[27]. Bruchez, Jr., M., Moronne, M., Gin, P., Weiss, S., Alivisatos, A.P., 1998. Semiconductor nanocrystals as fluorescent biological labels. Science 281, 2013–2016.

[28]. Oghabian, M.A., Farahbakhsh, N.M., 2010. Potential use of nanoparticle based contrast agents in MRI: a molecular imaging perspective. J. Biomed. Nanotechnol. 6 (3), 203–213.

[29]. Brüggemann, M., Winter, G., Waldmann, H., Neuberger, M.S., 1989a. The immunogenicity of chimeric antibodies. J. Exp. Med. 170, 2153–2157

[30]. Varshochian, R., Riazi-Esfahani, M., Jeddi-Tehrani, M., Mahmoudi, A.R., Aghazadeh, S., Mahbod, M., Movassat, M., Atyabi, F., Sabzevari, A., Dinarvand, R., 2015. Albuminated PLGA nanoparticles containing bevacizumab intended for ocular neovascularization treatment. J. Biomed. Mater. Res. A 103 (10), 3148–3156.

[31]. Zhang X, Sorensen M, Fung MandSchooley R. Synergistic in vitro antiretroviral activity of a humanized monoclonal anti-cd4 antibody (tnx-355) and enfuvirtide (t-20). Antimicrob. Agen. Chemother. 2006; 50: 2231-2233. Link Retrieved from journal

[32]. Jacobson JM, Israel RJ, Lowy I, Ostrow NA, Vassilatos LS, et al. Treatment of advanced human immunodeficiency virus type 1 disease with the viral entry inhibitor pro 542. Antimicrobial agents and chemotherapy. 2004; 48 (2): 423-429. Link Retrieved from journal.https://doi.10.1128/AAC.48.2.423-429.2004

[33]. Pugach P, Ketas TJ, Michael EandMoore JP. Neutralizing antibody and anti-retroviral drug sensitivities of hiv-1 isolates resistant to small molecule ccr5 inhibitors. Virology. 2008; 377 (2): 401-407. Link Retrieved from journal.https://doi.org/10.1016/j.virol.2008.04.032

[34]. Murga JD, Franti M, Pevear DC, Maddon PJandOlson WC. Potent antiviral synergy between monoclonal antibody and small-molecule ccr5 inhibitors of human immunodeficiency virus type 1. Antimicrobial agents and chemotherapy. 2006; 50 (10): 3289-3296. Link Retrieved from journal.https://doi.10.1128/AAC.00699-06